Treatment of Danhong Injection Combined with Naoxintong Capsule in Acute Coronary Syndrome Patients Undergoing PCI Operation: Study for a Randomized Controlled and Double‐Blind Trial

Abstract

Objective This double-blind and randomized placebo-controlled trial evaluated the safety and efficacy of Danhong injection combined with Naoxintong capsule in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). Methods ACS patients scheduled to undergo PCI (n = 130) were equally and randomly apportioned to either a treatment or control group. After PCI, the treatment group received Danhong injection combined with Naoxintong capsule for 12 weeks, while the control group was given placebo. Both groups were otherwise treated with conventional secondary prevention of coronary artery disease. The groups were primarily evaluated for clinical efficacy and cardiovascular events. Evaluative indicators of safety included adverse events, platelet count, and liver, renal, and blood coagulation functions. Result No cardiovascular events or adverse reactions were observed in either group. The treatment group demonstrated better signs of clinical efficacy, including left ventricular ejection fraction, higher nitric oxide levels, and lower levels of endothelin-1 (ET-1) and von Willebrand factor (VWF). Conclusion ACS patients treated with Danhong injection combined with Naoxintong capsule after PCI demonstrated better improvement with regard to markers associated with atherosclerosis and adverse cardiovascular events, without apparent adverse effects. Thus, Danhong injection combined with Naoxintong capsule was safe and effective for treating ACS patients after PCI.

Comparison of the clinical features and therapeutics of COVID-19 in cardio-cerebrovascular disease (CCVD) and non-CCVD patients

“…Z20026866). DHI is extracted from Salviae miltiorrhizae Radix and Carthami tinctorii Flos, and it can be used to treat CCVD [26][27][28][29][30].…”

Evaluation of the anti-inflammatory and antioxidant pharmcodynamic compoents of naoxintong capsules as a basis of broad spectrum effects

“…NXT also can reduce the NO level and the expression of inducible nitric oxide synthase (iNOS) in the vessel wall to treat atheromatous (Zhong et al 2013). In clinics, NXT can be used for carotid atherosclerosis and cerebral infarction (Liang et al 2018), partly abrogate the impaired protective effect of high-density lipoprotein (HDL) on endothelial function (Lv et al 2016), and improve adverse cardiovascular events, atherosclerosis, and the expression of inflammatory factors in patients with acute coronary syndrome undergoing PCI, when combined with Danhong injection (Lv et al 2015;Zhao et al 2018).…”

Danhong Injection Combined With Naoxintong Capsule in Patients With Acute Coronary Syndrome Patients Undergoing PCI: Study Protocol for a Randomized Controlled Trial

“…Various studies indicated that DHI and NXTC have various pharmacological functions including improvement in endothelial action, anti-in ammatory, antioxidant properties, and antithrombotic effects [18][19][20][21][22]. Clinical studies found that DHI and NXTC can have the effects of regulating blood glucose, regulating blood lipids, antiplatelet, anticoagulation, improving heart function, improving endothelial function, improving symptoms, improving quality of life in patients with ACS [23][24]. However, due to the small sample size and unscienti c research methods, the conclusions are limited.…”